JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
KR20170091801A
(ko)
|
2008-10-02 |
2017-08-09 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd86 길항제 다중-표적 결합 단백질
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
BRPI1010297A2
(pt)
|
2009-04-07 |
2017-06-06 |
Roche Glycart Ag |
anticorpos biespecíficos trivalentes.
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
JO3182B1
(ar)
*
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
BR112012005893A2
(pt)
|
2009-09-16 |
2016-11-22 |
Genentech Inc |
hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
|
CN102958942A
(zh)
*
|
2009-12-29 |
2013-03-06 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
RU2013104039A
(ru)
|
2010-07-19 |
2014-08-27 |
Ф. Хоффманн-Ля Рош Аг |
Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
|
WO2012010551A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
MX2013001305A
(es)
|
2010-08-05 |
2013-03-20 |
Hoffmann La Roche |
Proteina de fusion de citoquina anti-viral de anticuerpo anti-mhc.
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
TW201309330A
(zh)
*
|
2011-01-28 |
2013-03-01 |
Abbott Lab |
包含糖基化抗體之組合物及其用途
|
EP2681240B1
(en)
|
2011-02-28 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Monovalent antigen binding proteins
|
KR101638224B1
(ko)
|
2011-02-28 |
2016-07-08 |
에프. 호프만-라 로슈 아게 |
항원 결합 단백질
|
KR101517320B1
(ko)
|
2011-04-19 |
2015-05-28 |
메리맥 파마슈티컬즈, 인크. |
단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
AR086982A1
(es)
|
2011-06-22 |
2014-02-05 |
Hoffmann La Roche |
Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
|
JP6060162B2
(ja)
*
|
2011-08-23 |
2017-01-11 |
ロシュ グリクアート アーゲー |
2つのFabフラグメントを含むFc不含抗体および使用方法
|
EP2747781B1
(en)
*
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
HUE039703T2
(hu)
*
|
2011-08-23 |
2019-01-28 |
Roche Glycart Ag |
Bispecifikus antigénkötõ molekulák
|
RS56879B1
(sr)
*
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
|
US20130078250A1
(en)
*
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
AU2012316859A1
(en)
|
2011-09-29 |
2014-04-17 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
EP2795335B1
(en)
|
2011-12-19 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Method for the detection of free binding partner of a multispecific binder
|
KR20140107295A
(ko)
|
2011-12-22 |
2014-09-04 |
에프. 호프만-라 로슈 아게 |
진핵 세포용 전장 항체 표시 시스템 및 그것의 용도
|
PL2794878T3
(pl)
|
2011-12-22 |
2020-07-27 |
F.Hoffmann-La Roche Ag |
Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
|
KR102285184B1
(ko)
|
2011-12-22 |
2021-08-03 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성원 조합, 신규한 제조 세포 생성 방법 및 폴리펩티드의 재조합적 제조를 위한 그의 용도
|
CA2860914A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
CN104105966B
(zh)
|
2012-02-01 |
2016-10-26 |
弗·哈夫曼-拉罗切有限公司 |
用于检测多特异性结合物的结合搭档的方法
|
CN104379601B
(zh)
|
2012-02-03 |
2021-04-09 |
霍夫曼-拉罗奇有限公司 |
双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
ES2676031T3
(es)
|
2012-02-15 |
2018-07-16 |
F. Hoffmann-La Roche Ag |
Cromatografía de afinidad basada en el receptor Fc
|
US20150110788A1
(en)
*
|
2012-03-06 |
2015-04-23 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
BR112014025830A8
(pt)
|
2012-04-20 |
2017-10-10 |
Emergent Product Dev Seattle |
Polipeptídeos de ligação ao cd3
|
JP2015520168A
(ja)
*
|
2012-05-24 |
2015-07-16 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
多重特異性抗体
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CN104395339A
(zh)
|
2012-06-27 |
2015-03-04 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
RU2630296C2
(ru)
|
2012-07-04 |
2017-09-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к биотину и способы их применения
|
NZ701040A
(en)
|
2012-07-04 |
2017-02-24 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
SI2869837T1
(sl)
|
2012-07-04 |
2016-12-30 |
F. Hoffmann-La Roche Ag |
Protitelesa proti teofilinu in postopki uporabe
|
MX346146B
(es)
|
2012-07-13 |
2017-03-09 |
Hoffmann La Roche |
Metodo para detectar un aglutinante multiespecifico.
|
IN2015DN01299A
(ru)
*
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
CA2879499A1
(en)
|
2012-09-14 |
2014-03-20 |
F. Hoffmann-La Roche Ag |
Method for the production and selection of molecules comprising at least two different entities and uses thereof
|
WO2014054804A1
(ja)
*
|
2012-10-05 |
2014-04-10 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
US10590202B2
(en)
*
|
2012-11-19 |
2020-03-17 |
Baliopharm Ag |
Recombinant bispecific antibody binding to CD20 and CD95
|
CA3206122A1
(en)
|
2012-11-28 |
2014-06-05 |
Zymeworks Bc Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
KR101833602B1
(ko)
*
|
2013-02-26 |
2018-02-28 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
EP2961773B1
(en)
*
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
CA2896359A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP2970485A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Merck Patent GmbH |
Tetravalent bispecific antibodies
|
KR102049990B1
(ko)
*
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
MX365787B
(es)
|
2013-04-29 |
2019-06-14 |
Hoffmann La Roche |
Anticuerpos modificados de unión a receptor de fc neonatal (fcrn) humano y uso de los mismos.
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
RU2019108429A
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
|
WO2015025054A1
(en)
|
2013-08-22 |
2015-02-26 |
Medizinische Universität Wien |
Dye-specific antibodies for prestained molecular weight markers and methods producing the same
|
EP3055329B1
(en)
|
2013-10-11 |
2018-06-13 |
F. Hoffmann-La Roche AG |
Multispecific domain exchanged common variable light chain antibodies
|
CN104558194B
(zh)
*
|
2013-10-17 |
2018-04-27 |
泰州迈博太科药业有限公司 |
一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
|
KR102202925B1
(ko)
|
2013-11-21 |
2021-01-14 |
에프. 호프만-라 로슈 아게 |
항-알파-시누클레인 항체 및 사용 방법
|
CA2925677A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
MX2016007208A
(es)
|
2013-12-20 |
2016-07-21 |
Hoffmann La Roche |
Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合egfr及met之多功能抗體
|
EP3960768A1
(en)
|
2014-01-03 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
CA2930154A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
MX2016008190A
(es)
|
2014-01-06 |
2016-10-21 |
Hoffmann La Roche |
Modulos de lanzadera de barrera cerebral sanguinea monovalente.
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
KR20230022270A
(ko)
|
2014-03-28 |
2023-02-14 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
KR102376287B1
(ko)
|
2014-04-02 |
2022-03-17 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
|
TWI726842B
(zh)
|
2014-04-07 |
2021-05-11 |
日商中外製藥股份有限公司 |
免疫活化抗原結合分子
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
KR102223502B1
(ko)
*
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
TW201623333A
(zh)
|
2014-05-13 |
2016-07-01 |
Chugai Pharmaceutical Co Ltd |
對具有免疫抑制機能之細胞的t細胞重定向抗原結合分子
|
EA201692476A1
(ru)
|
2014-05-28 |
2017-07-31 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
SG10201913680PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
WO2016001810A1
(en)
|
2014-07-01 |
2016-01-07 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
RU2742493C2
(ru)
|
2014-07-10 |
2021-02-08 |
Аффирис Аг |
Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона
|
NZ766556A
(en)
|
2014-08-04 |
2024-02-23 |
Hoffmann La Roche |
Bispecific t cell activating antigen binding molecules
|
CU20170041A7
(es)
|
2014-09-26 |
2017-09-06 |
Macrogenics Inc |
Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
修飾されたFcRn結合特性およびプロテインA結合特性を有するFc領域変種
|
ES2749383T3
(es)
|
2014-11-06 |
2020-03-20 |
Hoffmann La Roche |
Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
AU2015353409B2
(en)
|
2014-11-26 |
2019-05-09 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
WO2016087514A1
(en)
|
2014-12-02 |
2016-06-09 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
EP3227332B1
(en)
*
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
JP6904902B2
(ja)
*
|
2014-12-05 |
2021-07-21 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
ドメイン交換抗体
|
KR20170094787A
(ko)
|
2014-12-18 |
2017-08-21 |
에프. 호프만-라 로슈 아게 |
Cdc 유발 항체를 측정하기 위한 검정 및 방법
|
WO2016105450A2
(en)
*
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
TWI688572B
(zh)
|
2015-01-26 |
2020-03-21 |
美商宏觀基因股份有限公司 |
包含dr5-結合結構域的多價分子
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
KR20180021875A
(ko)
*
|
2015-06-30 |
2018-03-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
다중특이적 결합 단백질
|
GEP20227438B
(en)
|
2015-07-30 |
2022-11-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
AU2016329111A1
(en)
|
2015-10-02 |
2018-02-08 |
F. Hoffmann-La Roche Ag |
Bispecific anti-CEAXCD3 T cell activating antigen binding molecules
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
KR20180069839A
(ko)
|
2015-10-08 |
2018-06-25 |
자임워크스 인코포레이티드 |
카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
|
WO2017062619A2
(en)
|
2015-10-08 |
2017-04-13 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
CN108350066B
(zh)
|
2015-10-29 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
CA2997406A1
(en)
|
2015-12-09 |
2017-06-15 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
EP3389714A4
(en)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
|
JP7088454B2
(ja)
|
2015-12-30 |
2022-06-21 |
コディアック サイエンシーズ インコーポレイテッド |
抗体および抗体複合体
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
EP3432927A4
(en)
*
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
JP7002467B2
(ja)
|
2016-04-15 |
2022-01-20 |
マクロジェニクス,インコーポレーテッド |
新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
CA3030841A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ
|
AU2017337073A1
(en)
*
|
2016-09-30 |
2019-04-18 |
Baylor College Of Medicine |
Antibody based gene therapy with tissue-directed expression
|
AU2017342560B2
(en)
|
2016-10-14 |
2022-03-17 |
Xencor, Inc. |
IL15/IL15Ralpha heterodimeric Fc-fusion proteins
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
US20230192896A1
(en)
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
MX2019007411A
(es)
|
2016-12-21 |
2019-08-29 |
Hoffmann La Roche |
Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
|
CN117887794A
(zh)
|
2016-12-21 |
2024-04-16 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
CN110088291A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
EP3558368A4
(en)
|
2016-12-23 |
2020-12-30 |
MacroGenics, Inc. |
ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE
|
KR20190113870A
(ko)
|
2017-02-02 |
2019-10-08 |
메르크 파텐트 게엠베하 |
항체 도메인의 바람직한 페어링
|
IL268836B2
(en)
|
2017-02-24 |
2024-04-01 |
Macrogenics Inc |
Bispecific molecules that bind CD137 and cancer antigens and their uses
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
DK3606954T3
(en)
|
2017-04-05 |
2022-09-26 |
Hoffmann La Roche |
Anti-LAG3-antistoffer
|
EP3645048A4
(en)
*
|
2017-06-25 |
2021-06-16 |
Systimmune, Inc. |
MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
|
WO2019005639A2
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
JP7245793B2
(ja)
|
2017-06-30 |
2023-03-24 |
ザイムワークス ビーシー インコーポレイテッド |
安定化したキメラFab
|
US11414478B2
(en)
|
2017-07-21 |
2022-08-16 |
Trianni, Inc. |
Single chain VH and heavy chain antibodies
|
US11161911B2
(en)
|
2017-10-23 |
2021-11-02 |
Go Therapeutics, Inc. |
Anti-glyco-MUC1 antibodies and their uses
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP7161534B2
(ja)
|
2017-11-29 |
2022-10-26 |
エフ.ホフマン-ラ ロシュ アーゲー |
標的による干渉が抑制された抗薬物抗体アッセイ
|
SG11202005557TA
(en)
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
KR20200100098A
(ko)
|
2017-12-19 |
2020-08-25 |
젠코어 인코포레이티드 |
조작된 il-2 fc 융합 단백질
|
US11192957B2
(en)
|
2017-12-21 |
2021-12-07 |
Hoffmann-La Roche Inc. |
Antibodies binding to HLA-A2/WT1
|
WO2019122054A1
(en)
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
CN111511400A
(zh)
|
2017-12-29 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗vegf抗体及其使用方法
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Lag3に結合する抗原結合部位を含む二重特異性抗体
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019160904A1
(en)
|
2018-02-15 |
2019-08-22 |
Macrogenics, Inc. |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
AR115318A1
(es)
|
2018-03-29 |
2020-12-23 |
Genentech Inc |
Modulación de la actividad lactogénica en células de mamífero
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
US11746157B2
(en)
|
2018-05-24 |
2023-09-05 |
Janssen Biotech, Inc. |
PSMA binding agents and uses thereof
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
SG11202100746WA
(en)
|
2018-07-25 |
2021-03-30 |
Innovent Biologics Suzhou Co Ltd |
Anti-tigit antibody and use thereof
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
CN109633053B
(zh)
*
|
2018-12-19 |
2021-04-30 |
杭州奕安济世生物药业有限公司 |
细胞培养物蛋白质表达量和蛋白质聚集体量的检测方法
|
SG10202105790QA
(en)
|
2018-12-21 |
2021-07-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
EP3902823A1
(en)
|
2018-12-24 |
2021-11-03 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
WO2020141117A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Ph-gradient spr-based binding assay
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
WO2020200944A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Method for generating avid-binding multispecific antibodies
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
WO2020229378A1
(en)
|
2019-05-13 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Interference-suppressed pharmacokinetic immunoassay
|
WO2020254352A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
EP3986924A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
MX2021015537A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
|
EP3986926A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CN114080451B
(zh)
|
2019-06-19 |
2024-03-22 |
豪夫迈·罗氏有限公司 |
通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
|
BR112021026286A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Método para aumentar o título de polipeptídeo heterólogo e/ou reduzir a produção de lactato de uma célula de mamífero recombinante e métodos para produzir um polipeptídeo heterólogo e uma célula de mamífero recombinante
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
BR112022002067A2
(pt)
*
|
2019-08-08 |
2022-06-14 |
Regeneron Pharma |
Formatos de molécula de ligação ao antígeno
|
CN114423791A
(zh)
|
2019-09-18 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
KR20220101079A
(ko)
|
2019-11-15 |
2022-07-19 |
에프. 호프만-라 로슈 아게 |
단백질 수용액 내 가시적 입자 형성의 방지
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
CN115515678A
(zh)
|
2019-12-23 |
2022-12-23 |
基因泰克公司 |
载脂蛋白l1特异性抗体及其使用方法
|
JP2023508596A
(ja)
|
2020-01-02 |
2023-03-02 |
エフ. ホフマン-ラ ロシュ アーゲー |
脳内の治療用抗体の量を決定するための方法
|
JP2023510382A
(ja)
|
2020-01-15 |
2023-03-13 |
エフ. ホフマン-ラ ロシュ アーゲー |
組換えタンパク質製造プロセスから不純物を減少させる方法
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
CN115605184A
(zh)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
防止胃肠外蛋白质溶液中的可见颗粒形成
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
AU2021288916A1
(en)
|
2020-06-08 |
2022-11-24 |
F.Hoffmann-La Roche Ag |
Anti-HBV antibodies and methods of use
|
IL298923A
(en)
|
2020-06-16 |
2023-02-01 |
Hoffmann La Roche |
A method for determining the free antigen of an antibody in a sample
|
JP2023531625A
(ja)
|
2020-06-19 |
2023-07-25 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CD3及びFolR1に結合する抗体
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies bind to cd3
|
IL298402A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies that bind to CD3 and CD19
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
WO2022010798A1
(en)
|
2020-07-06 |
2022-01-13 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
WO2022008468A1
(en)
|
2020-07-07 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
CA3185122A1
(en)
|
2020-07-17 |
2022-01-20 |
Cecilia Pui Chi Chiu |
Anti-notch2 antibodies and methods of use
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
EP4204558A2
(en)
|
2020-08-28 |
2023-07-05 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
EP4214244A1
(en)
|
2020-09-21 |
2023-07-26 |
Genentech, Inc. |
Purification of multispecific antibodies
|
CA3195257A1
(en)
|
2020-09-24 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with gene knockout
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
CN116782937A
(zh)
|
2020-12-10 |
2023-09-19 |
优特力克斯有限公司 |
抗pd-1抗体及其用途
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
ANTI-HLA-G antibodies and their use
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
CN117098548A
(zh)
|
2020-12-23 |
2023-11-21 |
信达生物制药(苏州)有限公司 |
抗b7-h3抗体及其用途
|
WO2022146003A1
(ko)
*
|
2020-12-29 |
2022-07-07 |
삼성바이오로직스 주식회사 |
이중 또는 다중 특이적 항체
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
CA3210246A1
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ. ホフマン-ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
TWI830151B
(zh)
*
|
2021-02-19 |
2024-01-21 |
大陸商信達生物製藥(蘇州)有限公司 |
抗GPRC5DxBCMAxCD3三特異性抗體及其用途
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
EP4304732A1
(en)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック, インコーポレイテッド |
改変された哺乳動物細胞
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
TW202317625A
(zh)
*
|
2021-06-17 |
2023-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
新穎三特異性結合分子
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
KR20240032930A
(ko)
|
2021-07-13 |
2024-03-12 |
제넨테크, 인크. |
사이토카인 방출 증후군을 예측하기 위한 다변량 모델
|
WO2023284806A1
(zh)
*
|
2021-07-14 |
2023-01-19 |
江苏恒瑞医药股份有限公司 |
特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
CN117805397A
(zh)
*
|
2024-02-29 |
2024-04-02 |
军科正源(北京)药物研究有限责任公司 |
检测游离vegf的方法
|